RTTNews | Dec 6, 2021 08:50AM EST

08:50 Monday, December 6, 2021 (RTTNews.com) - AbbVie (ABBV) announced positive results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission and endoscopic responsec at week 12.

The study showed that a significantly higher proportion of upadacitinib-treated patients achieved steroid-free clinical remission at week 12 compared to placebo.

The safety results in the study were consistent with the known profile of upadacitinib, with no new safety risks observed.

Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral therapy for moderate to severe Crohn's disease and several other immune-mediated inflammatory diseases.

Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal (or digestive) tract, causing persistent diarrhea and abdominal pain.

Read the original article on RTTNews ( https://www.rttnews.com/3247090/abbvie-s-upadacitinib-achieves-primary-secondary-endpoints-in-phase-3-study-on-crohn-s-disease.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved